JP2020510426A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020510426A5 JP2020510426A5 JP2019546855A JP2019546855A JP2020510426A5 JP 2020510426 A5 JP2020510426 A5 JP 2020510426A5 JP 2019546855 A JP2019546855 A JP 2019546855A JP 2019546855 A JP2019546855 A JP 2019546855A JP 2020510426 A5 JP2020510426 A5 JP 2020510426A5
- Authority
- JP
- Japan
- Prior art keywords
- rna
- region
- protein
- mrna
- coding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022209557A JP2023052106A (ja) | 2017-02-28 | 2022-12-27 | 翻訳可能分子およびその合成 |
| JP2025159744A JP2026016392A (ja) | 2017-02-28 | 2025-09-26 | 翻訳可能分子およびその合成 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762465073P | 2017-02-28 | 2017-02-28 | |
| US62/465,073 | 2017-02-28 | ||
| PCT/US2018/020018 WO2018160592A1 (en) | 2017-02-28 | 2018-02-27 | Translatable molecules and synthesis thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022209557A Division JP2023052106A (ja) | 2017-02-28 | 2022-12-27 | 翻訳可能分子およびその合成 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020510426A JP2020510426A (ja) | 2020-04-09 |
| JP2020510426A5 true JP2020510426A5 (enExample) | 2021-04-15 |
| JP7674077B2 JP7674077B2 (ja) | 2025-05-09 |
Family
ID=63370513
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019546855A Active JP7674077B2 (ja) | 2017-02-28 | 2018-02-27 | 翻訳可能分子およびその合成 |
| JP2022209557A Pending JP2023052106A (ja) | 2017-02-28 | 2022-12-27 | 翻訳可能分子およびその合成 |
| JP2025159744A Pending JP2026016392A (ja) | 2017-02-28 | 2025-09-26 | 翻訳可能分子およびその合成 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022209557A Pending JP2023052106A (ja) | 2017-02-28 | 2022-12-27 | 翻訳可能分子およびその合成 |
| JP2025159744A Pending JP2026016392A (ja) | 2017-02-28 | 2025-09-26 | 翻訳可能分子およびその合成 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US11407800B2 (enExample) |
| EP (1) | EP3589290A4 (enExample) |
| JP (3) | JP7674077B2 (enExample) |
| WO (1) | WO2018160592A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018160592A1 (en) | 2017-02-28 | 2018-09-07 | Arcturus Therapeutics, Inc. | Translatable molecules and synthesis thereof |
| CA3122080A1 (en) | 2018-12-06 | 2020-06-11 | Arcturus Therapeutics, Inc. | Compositions and methods for treating ornithine transcarbamylase deficiency |
| CN110331147A (zh) * | 2019-06-21 | 2019-10-15 | 苏州吉玛基因股份有限公司 | 一种mRNA的制备方法及其在肿瘤治疗中的应用 |
| WO2021178510A1 (en) | 2020-03-03 | 2021-09-10 | Arcturus Therapeutics, Inc. | Compositions and methods for the treatment of ornithine transcarbamylase deficiency |
| JP2023517644A (ja) | 2020-03-09 | 2023-04-26 | アークトゥラス・セラピューティクス・インコーポレイテッド | コロナウイルスワクチン組成物及び方法 |
| EP4143217A4 (en) | 2020-05-01 | 2024-10-02 | Arcturus Therapeutics, Inc. | NUCLEIC ACIDS AND METHODS FOR TREATING CYSTIC FIBROSIS |
| CN116171150A (zh) | 2020-08-14 | 2023-05-26 | 阿克丘勒斯治疗公司 | 冻干脂质纳米颗粒的方法 |
| CA3128660A1 (en) * | 2020-10-09 | 2022-04-09 | Eric G. Marcusson | Compositions and methods for the prevention and/or treatment of covid-19 |
| CN113372432A (zh) * | 2021-06-15 | 2021-09-10 | 深圳市臻质医疗科技有限公司 | 一种基于化学修饰mRNA编码蛋白因子诱导和/或增强软骨损伤修复的方法 |
| KR102785258B1 (ko) * | 2022-09-07 | 2025-03-26 | 아이진 주식회사 | 변형핵산 함유 mRNA의 체내 전달용 조성물 |
| EP4356933A1 (en) * | 2022-09-07 | 2024-04-24 | Eyegene, Inc. | Composition for delivering modified nucleic acid-containing mrna |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2842964A1 (de) | 2001-06-05 | 2015-03-04 | Curevac GmbH | Virtuelles Verfahren zur Ermittlung einer modifzierten mRNA-Sequenz |
| AU2002338926B2 (en) * | 2001-11-05 | 2007-05-24 | Janssen Pharmaceutica N.V. | Method for the in vitro synthesis of short double stranded RNAs |
| RS63964B1 (sr) * | 2005-08-23 | 2023-03-31 | Univ Pennsylvania | Rnk koja sadrži modifikovane nukleozide i postupci za njenu upotrebu |
| WO2008016473A2 (en) | 2006-07-28 | 2008-02-07 | Applera Corporation | Dinucleotide mrna cap analogs |
| WO2009058911A2 (en) | 2007-10-31 | 2009-05-07 | Applied Biosystems Inc. | Preparation and isolation of 5' capped mrna |
| US20090226906A1 (en) | 2008-03-05 | 2009-09-10 | Helicos Biosciences Corporation | Methods and compositions for reducing nucleotide impurities |
| JP6113737B2 (ja) | 2011-10-03 | 2017-04-12 | モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． | 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法 |
| EP2834259A4 (en) | 2012-04-02 | 2016-08-24 | Moderna Therapeutics Inc | MODIFIED POLYNUCLEOTIDES |
| US9283287B2 (en) * | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| MX363017B (es) | 2012-11-01 | 2019-03-04 | Factor Bioscience Inc | Métodos y productos para la expresión de proteínas en células. |
| US9597380B2 (en) | 2012-11-26 | 2017-03-21 | Modernatx, Inc. | Terminally modified RNA |
| SG11201510747RA (en) | 2013-08-21 | 2016-03-30 | Curevac Ag | Method for increasing expression of rna-encoded proteins |
| EP3052511A4 (en) | 2013-10-02 | 2017-05-31 | Moderna Therapeutics, Inc. | Polynucleotide molecules and uses thereof |
| EA201992208A1 (ru) | 2013-10-22 | 2020-07-31 | Транслейт Био, Инк. | ЛЕЧЕНИЕ ФЕНИЛКЕТОНУРИИ С ПРИМЕНЕНИЕМ мРНК |
| GB201403096D0 (en) * | 2014-02-21 | 2014-04-09 | Oxford Nanopore Tech Ltd | Sample preparation method |
| JP6728156B2 (ja) | 2014-11-02 | 2020-07-22 | アークトゥラス・セラピューティクス・インコーポレイテッドＡｒｃｔｕｒｕｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | メッセンジャーｕｎａ分子およびその使用 |
| EP3041948B1 (en) | 2014-11-10 | 2019-01-09 | Modernatx, Inc. | Alternative nucleic acid molecules containing reduced uracil content and uses thereof |
| EP4324473A3 (en) * | 2014-11-10 | 2024-05-29 | ModernaTX, Inc. | Multiparametric nucleic acid optimization |
| WO2017201317A1 (en) * | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polyribonucleotides containing reduced uracil content and uses thereof |
| WO2018160592A1 (en) | 2017-02-28 | 2018-09-07 | Arcturus Therapeutics, Inc. | Translatable molecules and synthesis thereof |
-
2018
- 2018-02-27 WO PCT/US2018/020018 patent/WO2018160592A1/en not_active Ceased
- 2018-02-27 JP JP2019546855A patent/JP7674077B2/ja active Active
- 2018-02-27 EP EP18761078.7A patent/EP3589290A4/en active Pending
- 2018-02-27 US US15/907,123 patent/US11407800B2/en active Active
-
2022
- 2022-07-14 US US17/812,576 patent/US11939363B2/en active Active
- 2022-12-27 JP JP2022209557A patent/JP2023052106A/ja active Pending
-
2025
- 2025-09-26 JP JP2025159744A patent/JP2026016392A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020510426A5 (enExample) | ||
| Tusup et al. | Design of in vitro transcribed mRNA vectors for research and therapy | |
| JP2010530245A5 (enExample) | ||
| AU2017226199A1 (en) | Virus vectors expressing multiple epitopes of tumor associated antigens for inducing antitumor immunity | |
| JP2008056679A5 (enExample) | ||
| WO2013018778A1 (ja) | ウィルムス腫瘍遺伝子産物またはその断片をコードしている改変型核酸構築物を含んでいる免疫治療用細胞、当該細胞の製造方法、および当該核酸構築物 | |
| JP2015513897A5 (enExample) | ||
| JP2004501646A5 (enExample) | ||
| CN106459997A (zh) | 用于疫苗应用的高效价病毒样囊泡的进化 | |
| WO2018212361A1 (en) | Method of treating diseases associated with myd88 pathways using crispr-gndm system | |
| CN117165611A (zh) | 一种构建mRNA体外转录模板的骨架 | |
| CA2555013A1 (en) | Carcinoembryonic antigen fusions and uses thereof | |
| CN115485379A (zh) | 用于体外mRNA转录的合成DNA模板 | |
| JP2025114633A (ja) | インビトロトランスクリプトｍｒｎａ及びこれを含有する薬学組成物 | |
| EP3158060B1 (en) | Method for rapid generation of an infectious rna virus | |
| CN120641560A (zh) | Rna聚合酶变体及其应用 | |
| JP2025520106A (ja) | Ｍｒｎａの細胞内安定性と生合成を向上させるｕｔｒ配列を含む構成物とその使用 | |
| Xu et al. | From sequence to system: Enhancing IVT mRNA vaccine effectiveness through cutting-edge technologies | |
| CN119639774A (zh) | 自复制rna分子组合及其应用 | |
| EP4687969A1 (en) | Coronavirus vaccines inducing broad immunity against variants | |
| WO2023208118A9 (zh) | 核酸构建体及其应用 | |
| CN110577972B (zh) | CRISPR/Sa-ShaCas9基因编辑系统及其应用 | |
| JP2024509146A (ja) | コロナウイルスに対して保護するためのワクチン産生のための完全合成長鎖核酸 | |
| CN107759673B (zh) | 可对hbv的dna进行表观甲基化修饰的蛋白分子及其应用 | |
| JPWO2023066874A5 (enExample) |